Search
Now showing items 1-2 of 2
Spending on postapproval drug safety.
(Health Aff (Millwood), 2006-03)
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval
safety surveillance. There have been no systematic assessments of spending on postapproval
safety. We surveyed drug manufacturers regarding ...
Economic return of clinical trials performed under the pediatric exclusivity program.
(JAMA, 2007-02-07)
CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to
grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program
if industry sponsors complete FDA-requested pediatric ...